« Return to News | R&D Trends

Curie-Cancer, Sanofi collaborate

Wednesday, June 19, 2013 01:42 PM

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Carnot Institute, have established a three-year research collaboration to identify new therapeutic targets for developing treatments for ovarian cancer.

The aim is to revisit the basic biology of cancer through a translational research approach. The Curie Institute has a collection of cryopreserved tumor samples characterized clinically, histologically and biologically. These can be analyzed to identify biological targets relevant to the effective treatment of cancer. Sanofi and Curie-Cancer expect to gain a better understanding of the molecular alterations that characterize many types of ovarian cancer, thereby enabling effective new drugs to be designed.

"We hope this long-term collaboration will ultimately open up perspectives for new therapeutic options for women with this disease," said Debasish Roychowdhury, senior vice president and head of Sanofi oncology.

Using technology platforms developed at the Curie Institute, this program will make it possible to sequence molecules expressed by the tumor genome, compare the sequences of those obtained with non-tumor tissues from the same patients and then clarify and validate the nature of the molecular alterations identified. Sanofi will guide an assessment of the tumor's ability to be inhibited or stimulated by drugs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.